BioSpace News Archive

Asieris Pharmaceuticals, a China-based biotech company specializing in the development and commercialization of new drugs for the treatment of genitourinary tumors and related diseases, today announced that Australian regulatory authorities have approved its Phase I clinical trial of APL-1501

Conference Call and Webcast scheduled for tomorrow, October 29, 2020 at 10:00 am PT

CONMED Corporation (NYSE: CNMD) today announced financial results for the third quarter ended September 30, 2020. Third Quarter 2020 Highlights Sales of $237.8 million increased 1.8% year over year as reported and in constant currency. Domestic revenue increased 4.7% year over year. International revenue decreased 1.7% as reported and in constant currency. Diluted net earnings per share

MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial results for the third quarter of 2020 after the market closes on Wednesday, November 4, 2020. MacroGenics will host a conference call to discuss the financial results and recent corporate prog

Viemed Healthcare, Inc. (the “Company” or “Viemed”) (TSX: VMD.TO and NASDAQ:VMD), a home medical equipment supplier that provides post-acute respiratory care services in the United States, announced its support for the Centers for Medicare & Medicaid Services’ (“CMS”) recent decision to remove oxygen and positive airway pressure (“PAP”) devices from the Competitive Bidding Program (“CBP”) beginning January 1, 2021

PTC Therapeutics, Inc. announced that on October 23, 2020 it approved non-statutory stock options to purchase an aggregate of 18,610 shares of its common stock and 6,860 restricted stock units, each representing the right to receive one share of its common stock upon vesting, to 18 new employees.

Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that data from the IMerge Phase 2 trial were published in the Journal of Clinical Oncology. The article entitled, “Imetelstat Achieves Meaningful and Durable Transfusion Independence in High-Transfusion Burden Patients with Lower Risk Myelodysplastic Syndr

Therapeutic Systems Research Laboratories (TSRL, Inc.) is now accepting proposals for its 2021 cohort of portfolio technologies.

Teleflex Incorporated (NYSE:TFX), a leading global provider for healthcare supplies and services, today announced it has entered into a definitive agreement to acquire privately-held Z-Medica, LLC, an industry-leading manufacturer of hemostatic products. Under the terms of the agreement, Teleflex will acquire Z-Medica for an upfront cash payment of $500 million at closing, and up to an additional $25 million upon the achievement of certain commerci

The New England Journal of Medicine has published data from the monotherapy arms of BLAZE-1, a Phase 2 study assessing the efficacy and safety of Eli Lilly and Company’s (NYSE: LLY) bamlanivimab (LY-CoV555) – a neutralizing antibody – in the COVID-19 outpatient setting. This study focused on ambulatory COVID-19 patients being treat